Drug Pipeline

Q702 Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
3
Active Studies
1
Recruiting
2
Top Sponsors
2
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-05-30 NCT06445907
Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute…		 overall status: "Recruiting" → "Active Not Recruiting"
2026-05-30 NCT06445907
Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute…		 Enrollment reduced: 32 -> 17 participants
Active Studies by Phase
Phase 1/2
1
Phase 1
2
Active Trials
NCT IDTitleConditionStatus
Phase 1/2
NCT05438420 Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With… Esophageal Cancer Active, Not Recruiting
Phase 1
NCT07138196 A Study to Evaluate Adrixetinib (Q702) in Adults With Active Chronic Graft-Versus-Host… Chronic Graft-Versus-Host Disease Recruiting
NCT06445907 Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute… Acute Myeloid Leukemia Active, Not Recruiting
Sponsors Running Q702 Trials
Qurient Co., Ltd. (2) M.D. Anderson Cancer Center (1)
Disease Areas
Gastric Cancer (1) Cervical Cancer (1) Esophageal Cancer (1) Leukemia (1) Acute Myeloid Leukemia (AML) (1)
Get alerts when Q702 trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free